Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

(2014) J. A. Roberts et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration

(2014) Julie M. Varghese et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?

(2013) Gloria Wong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tissue Pharmacokinetics of Cefazolin in Patients with Lower Limb Infections

(2013) Amira A. Bhalodi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Augmented Renal Clearance in the ICU

(2013) Andrew A. Udy et al.   CRITICAL CARE MEDICINE

Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis

(2013) M. J. E. Brill et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian

(2013) Tatiana Tatarinova et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The Clinical Relevance of Plasma Protein Binding Changes

(2012) Jason A. Roberts et al.   CLINICAL PHARMACOKINETICS

Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*

(2012) Jason A. Roberts et al.   CRITICAL CARE MEDICINE

What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance

(2012) Andrew A. Udy et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R

(2012) Michael N. Neely et al.   THERAPEUTIC DRUG MONITORING

Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery

(2011) Alexandra Douglas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients

(2011) Andrew A. Udy et al.   CHEST

Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients

(2011) Jason A Roberts et al.   BMC Anesthesiology

The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients

(2010) Marta Ulldemolins et al.   CLINICAL PHARMACOKINETICS

Augmented Renal Clearance

(2009) Andrew A. Udy et al.   CLINICAL PHARMACOKINETICS

Antibiotic resistance—What’s dosing got to do with it?

(2009) Jason A. Roberts et al.   CRITICAL CARE MEDICINE

Pharmacokinetic issues for antibiotics in the critically ill patient

(2009) Jason A. Roberts et al.   CRITICAL CARE MEDICINE

Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?

(2009) Jason A. Roberts et al.   CRITICAL CARE MEDICINE

International Study of the Prevalence and Outcomes of Infection in Intensive Care Units

(2009) Jean-Louis Vincent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution

(2009) Jason A. Roberts et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY